A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS

Collection UNKNOWN
de Barra, Eoghan; H. Hodgson, Susanne; J. Ewer, Katie; M. Bliss, Carly; Hennigan, Kerrie; Collins, Ann; Berrie, Eleanor; M. Lawrie, Alison; C. Gilbert, Sarah; Nicosia, Alfredo; J. McConkey, Samuel; V. S. Hill, Adrian;
  • Publisher: Figshare
  • Related identifiers: doi: 10.1371/journal.pone.0115161
  • Subject: Biological Sciences | day 14 post ChAd 63 CS | sfc | circumsporozoite protein | ELIspot 7 days | Phase Ia | vectored vaccines encoding | immunogenic delivery platform | day 140 | pbmc | chimpanzee adenovirus 63 | vaccinia virus Ankara | Phase Ia Study | antibody concentration | New Malaria Vaccine Candidates ChAd 63 CS Administered | ChAd 63 CS dose | day 14 | antibody concentration groups 1 B | CS antigen | T cell responses | nct | MVA CS BackgroundPlasmodium falciparum

<div><p>Background</p><p>Plasmodium falciparum (P. falciparum) malaria remains a significant cause of mortality and morbidity throughout the world. Development of an effective vaccine would be a key intervention to reduce the considerable social and economic impact of m... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection)
  • Cite this research product